News | October 13, 2008

GE Launches New PET/CT at European Nuclear Medicine Meeting

October 14, 2008 - GE Healthcare introduced Discovery PET/CT 600, its newest positron emission tomography/computed tomography (PET/CT) system at the annual meeting of the European Association of Nuclear Medicine (EANM) Congress in Munich.

Recently cleared by the FDA, Discovery PET/CT 600 is part of GE’s Discovery family of scanners designed to enable earlier detection and accurate monitoring of disease with molecular imaging technology in both hardware and software.

Discovery PET/CT 600 is optimized for use in oncology, which represents more than 90 percent of clinical PET/CT exams. The system leverages the high-speed, high-resolution capabilities of GE’s BrightSpeed CT with the breakthrough motion management capabilities of its Discovery PET system. By combining these scanning technologies, the Discovery PET/CT 600 provides the tools to enable physicians to manage disease with more confidence.

As a key component of the image chain, the Discovery PET/CT 600 includes a scintillator with a proven track record and the highest sensitivity in the industry. GE BGO technology allows for improved lesion detectability, potentially reducing the dose requirement and allowing for faster scans and increased throughput.

For clinicians, the Discovery PET/CT 600 will provide a large 70cm bore that offers a full 70cm PET and CT Field-of-View and a ~225kg (500 lbs.) patient table. The GE Discovery PET/CT 600 offers an increased vertical scan range that provides more flexibility in radiation treatment planning and patient positioning.

“The Discovery PET/CT 600 platform was built for physicians and molecular imaging researchers based on their clinical need for more quantitative accuracy and the power to explore the potential of PET/CT imaging,” said Henry Hummel, general manager of GE Healthcare’s global PET/CT business.

For more information: www.gehealthcare.com

Related Content

Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...